The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167 · cited 1×
“reason for its survival in the CF lung, despite an exuberant inflammatory response and intensive antibiotic treatment [7,8].”
BackgroundAntibiotic resistance of bacteria in biofilms
Stewart, P. S., & William Costerton, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05321-1 · Cited by 4,585 · cited 1×
“However, antibiotics alone seem unable to resolve the problem of biofilm infections, not only because of biofilm resistance, but also because of dispersion limitations posed by the biofilm extracellular matrix [2,24,25].”
Understanding biofilm resistance to antibacterial agents
Davies, D. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1008 · Cited by 2,781 · cited 8×
“Adapted from Davies [3] Copyright © 2003, Rights Managed by Nature Publishing Group This complex process relies on the ability of bacteria to function cooperatively through a cell-cell communication process called quorum sensing.”
BackgroundMethodInfluentialSurvival strategies of infectious biofilms
Fux, C. A., Costerton, J. W., Stewart, P. S., & Stoodley, P. (2005) · Trends in Microbiology · doi:10.1016/j.tim.2004.11.010 · Cited by 1,812 · cited 1×
“However, antibiotics alone seem unable to resolve the problem of biofilm infections, not only because of biofilm resistance, but also because of dispersion limitations posed by the biofilm extracellular matrix [2,24,25].”
BackgroundLebeaux, D., Ghigo, J.-M., & Beloin, C. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00013-14 · Cited by 1,318 · cited 9×
“A very promising perspective, although still at an early stage of development, is the use of substances that are active against persister cells or that sensitize these cells to antimicrobial agents [2,23].”
BackgroundMethodInfluentialThe role of bacterial biofilms in chronic infections
Bjarnsholt, T. (2013) · APMIS · doi:10.1111/apm.12099 · Cited by 1,080
Hall-Stoodley, L., Hu, F. Z., Gieseke, A., Nistico, L., Nguyen, D., Hayes, J., Forbes, M., Greenberg, D. P., Dice, B., Burrows, A., et al. (2006) · JAMA · doi:10.1001/jama.296.2.202 · Cited by 878 · cited 3×
“beta-lactams, aminoglycosides) [2,3,20]; iii) the presence of persister cells that, due to their state, are highly resistant to antibiotics and can subsequently regenerate vegetative cells within the biofilm [2,3,20].”
BackgroundActivated ClpP kills persisters and eradicates a chronic biofilm infection
Conlon, B. P., Nakayasu, E. S., Fleck, L. E., LaFleur, M. D., Isabella, V. M., Coleman, K., Leonard, S. N., Smith, R. D., Adkins, J. N., & Lewis, K. (2013) · Nature · doi:10.1038/nature12790 · Cited by 672 · cited 1×
“A very promising perspective, although still at an early stage of development, is the use of substances that are active against persister cells or that sensitize these cells to antimicrobial agents [2,23].”
BackgroundPathogenesis of cystic fibrosis
Koch, C., & Høiby, N. (1993) · The Lancet · doi:10.1016/0140-6736(93)92422-p · Cited by 426 · cited 1×
“reason for its survival in the CF lung, despite an exuberant inflammatory response and intensive antibiotic treatment [7,8].”
BackgroundSafdar, N., Crnich, C. J., & Maki, D. G. (2005) · Respiratory Care · doi:10.4187/respcare.05500725 · Cited by 366
Dekhuijzen, P. N. R. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00016804 · Cited by 317 · cited 1×
“[58,59] A multicenter double blind study [60] on 180 patients with acute bronchitis, tracheobronchitis, or acute exacerbations of chronic bronchitis compared the effects of thiamphenicol glycinate acetylcysteinate (TGA;n=92) and thiamphenicol glycinate (TG; n=88), both administered by aerosol.”
BackgroundTunney, M. M., Einarsson, G. G., Wei, L., Drain, M., Klem, E. R., Cardwell, C., Ennis, M., Boucher, R. C., Wolfgang, M. C., & Elborn, J. S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201210-1937oc · Cited by 316 · cited 1×
“also been recently identified in patients with bronchiectasis [16,17].”
BackgroundCiofu, O., Tolker-Nielsen, T., Jensen, P. Ø., Wang, H., & Høiby, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.11.017 · Cited by 306 · cited 1×
“Other pathogens such as Burkholderia cepacia complex, Staphylococcus aureus, Achromobacter xylosoxidans, and Stenotrophomonas maltophilia have also been identified in CF and are related to biofilm formation [9].”
BackgroundManagement of bronchiectasis in adults
Chalmers, J. D., Aliberti, S., & Blasi, F. (2015) · European Respiratory Journal · doi:10.1183/09031936.00119114 · Cited by 286 · cited 2×
“NAC seems to be useful in this latter process, but the evidence to date is not sufficiently supported by clinical studies [15,61].”
BackgroundSelf-citationChronic Pseudomonas aeruginosa Infection in Chronic Obstructive Pulmonary Disease
Martínez‐Solano, L., Macia, M. D., Fajardo, A., Oliver, A., & Martinez, J. L. (2008) · Clinical Infectious Diseases · doi:10.1086/593186 · Cited by 257 · cited 13×
“Literature search methodology Literature searches, conducted in the period August-September 2015, were performed using the PubMed database (with no date limitations), searching with the terms ‘biofilm’, ‘respiratory tract infection’, ‘N-acetylcysteine’, ‘cystic fibrosis’, ‘COPD’, ‘bronchiectasis’, M AN US CR IP T AC C…”
BackgroundInfluentialOlofsson, A.-C., Hermansson, M., & Elwing, H. (2003) · Applied and Environmental Microbiology · doi:10.1128/aem.69.8.4814-4822.2003 · Cited by 249 · cited 7×
“…et al., 2009 [30] 2 and 4 Aslam et al., 2007 [34] 80 Olofsson et al., 2003 [35] range 0.25-2 Enterobacter cloacae Aslam and Darouiche, 2011 [33] 80 Olofsson et al., 2003 [35] range 0.25-2 Proteus spp. Mohsen et al., 2015 [32] 2.5 El Feki et al., 2009 [30] 2 and 4 Pseudomonas aeruginosa Mohsen et…”
BackgroundInfluentialGil-Perotin, S., Ramirez, P., Marti, V., Sahuquillo, J. M., Gonzalez, E., Calleja, I., Menendez, R., & Bonastre, J. (2012) · Critical Care · doi:10.1186/cc11357 · Cited by 241
N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa
Zhao, T., & Liu, Y. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-140 · Cited by 216 · cited 3×
“aeruginosa [38], which are known to be among the most important opportunistic pathogens that are responsible for biofilmassociated chronic respiratory colonization in patients with cystic fibrosis, COPD, and bronchiectasis.”
BackgroundVentilator Associated Pneumonia: Evolving Definitions and Preventive Strategies
Mietto, C., Pinciroli, R., Patel, N. G., & Berra, L. M. (2013) · Respiratory Care · doi:10.4187/respcare.02380 · Cited by 211
Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis
Chalmers, J. D., & Hill, A. T. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.09.011 · Cited by 200 · cited 1×
“assumed to play a relevant role in the pathophysiological cascade of this disease [13-15].”
BackgroundInfluence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A. G., Rogliani, P., & Gabriella Matera, M. (2015) · European Respiratory Review · doi:10.1183/16000617.00002215 · Cited by 198 · cited 1×
“M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT The role of NAC in preventing exacerbations of patients with COPD and chronic bronchitis has been the basis of a recent meta-analysis by Cazzola and colleagues [56].”
BackgroundSelf-citationCharacterization of Bacterial and Fungal Biofilms in Chronic Rhinosinusitis
Foreman, A., Psaltis, A. J., Tan, L. W., & Wormald, P.-J. (2009) · American Journal of Rhinology & Allergy · doi:10.2500/ajra.2009.23.3413 · Cited by 195 · cited 1×
“biofilms was strongly associated with persistent mucosal inflammation after endoscopic sinus surgery [22].”
BackgroundHigh-Dose N-Acetylcysteine in Stable COPD
Tse, H. N., Raiteri, L., Wong, K. Y., Yee, K. S., Ng, L. Y., Wai, K. Y., Loo, C. K., & Chan, M. H. (2013) · Chest · doi:10.1378/chest.12-2357 · Cited by 187 · cited 1×
“Furthermore, the data showed that in the case of airway obstruction, higher doses (≥1200 mg per day) are needed to prevent exacerbations[51, 57], while regular doses (600 mg per day) are sufficient in patients with chronic bronchitis.”
BackgroundInfluence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis
Perez-Giraldo, C. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/39.5.643 · Cited by 156 · cited 3×
“The ability of NAC to interfere with biofilm formation was first demonstrated by P erez-Giraldo and colleagues in 1997 [29].”
BackgroundInfluentialAslam, S., Trautner, B. W., Ramanathan, V., & Darouiche, R. O. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00893-06 · Cited by 132 · cited 4×
“…al., 2003 [31] range 0.007-8 Klebsiella pneumoniae Mohsen et al., 2015 [32] 2.5 Aslam and Darouiche, 2011 [33] 80 El Feki et al., 2009 [30] 2 and 4 Aslam et al., 2007 [34] 80 Olofsson et al., 2003 [35] range 0.25-2 Enterobacter cloacae Aslam and Darouiche, 2011 [33] 80 Olofsson et al., 2003 [35]…”
BackgroundInfluentialEffect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms
Marchese, A. E. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00232-2 · Cited by 129 · cited 1×
“Pathogens examined Reference NAC concentrations tested (mg/ml) Gram-negative bacteria Escherichia coli El Feki et al., 2009 [30] 2 and 4 Marchese et al., 2003 [31] range 0.007-8 Klebsiella pneumoniae Mohsen et al., 2015 [32] 2.5 Aslam and Darouiche, 2011 [33] 80 El Feki et al., 2009 [30] 2 and 4…”
BackgroundInfluentialBakaletz, L. O. (2012) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2012.03.001 · Cited by 121
Host-microbial interactions in patients with chronic rhinosinusitis
Hamilos, D. L. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.06.049 · Cited by 117
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis
Tam, J., Nash, E. F., Ratjen, F., Tullis, E., & Stephenson, A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007168.pub3 · Cited by 113
Conrad, C., Lymp, J. F., Thompson, V., Dunn, C. E., Davies, Z. A., Chatfield, B. A., Nichols, D. P., Clancy, J. P., Vender, R. L., Egan, M. E., et al. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.08.008 · Cited by 111 · cited 1×
“In another study [55], 70 CF subjects received NAC or placebo orally three times daily for 24 weeks.”
MethodHigh-Dose N-Acetylcysteine in??Patients with Exacerbations of??Chronic Obstructive Pulmonary Disease
Zuin, R., Palamidese, A., Negrin, R., Catozzo, L., Scarda, A., & Balbinot, M. (2005) · Clinical Drug Investigation · doi:10.2165/00044011-200525060-00005 · Cited by 106
N-Acetylcysteine Inhibits Growth and Eradicates Biofilm of Enterococcus faecalis
Quah, S. Y., Wu, S., Lui, J., Sum, C. P., & Tan, K. S. (2011) · Journal of Endodontics · doi:10.1016/j.joen.2011.10.004 · Cited by 105 · cited 2×
“…[30] 2 and 4 Venkatesh et al., 2009 [45] range 0.5-32 Aslam et al., 2007 [34] 80 Perez-Giraldo et al., 1997 [29] range 0.003-8 Enterococcus faecalis Quah et al., 2012 [46] range 12.5-50 Yeast Candida albicans El-Baky et al., 2014; [47] range 0.312-40 Venkatesh et al., 2009 [45] range 0.5-32 M…”
BackgroundInfluentialEl‐Feky, M. A., Elrehewy, M., Hassan, M. A., Abolella, H. A., El-Baky, R. M. A., & Gad, G. F. M. (2009) · PubMed · Cited by 92
Hassett, D. J., Borchers, M. T., & Panos, R. J. (2014) · The Journal of Microbiology · doi:10.1007/s12275-014-4068-2 · Cited by 88 · cited 13×
“Literature search methodology Literature searches, conducted in the period August-September 2015, were performed using the PubMed database (with no date limitations), searching with the terms ‘biofilm’, ‘respiratory tract infection’, ‘N-acetylcysteine’, ‘cystic fibrosis’, ‘COPD’, ‘bronchiectasis’, M AN US CR IP T AC C…”
BackgroundInfluentialPredominant pathogen competition and core microbiota divergence in chronic airway infection
Rogers, G. B., Gast, C., & Serisier, D. J. (2014) · The ISME Journal · doi:10.1038/ismej.2014.124 · Cited by 78
Bryers, J. D., Jarvis, R. A., Lebo, J., Prudencio, A., Kyriakides, T. R., & Uhrich, K. E. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.05.034 · Cited by 76
Novel synergistic antibiofilm combinations for salvage of infected catheters
Venkatesh, M., Rong, L., Raad, I., & Versalovic, J. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009761-0 · Cited by 67 · cited 3×
“, 2009 [45] range 0.”
BackgroundInfluentialdel Prado, G., Ruiz, V., Naves, P. L. F., Rodríguez-Cerrato, V., Soriano, F. G., & Ponte, M. D. C. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.03.016 · Cited by 66
Olofsson, A.-C., Hermansson, M., & Elwing, H. B. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.5.2705-2712.2005 · Cited by 64 · cited 1×
“paper mills) have raised a multidisciplinary interest for this molecule [35,52].”
BackgroundEldika, N., & Sethi, S. (2006) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000208451.50231.8f · Cited by 63
Kashef, N., Karami, S., & Djavid, G. E. (2015) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2015.04.001 · Cited by 48 · cited 1×
“aureus biofilms [48].”
Moon, J.-H., Jang, E.-Y., Shim, K. S., & Lee, J. Y. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-4500-2 · Cited by 46 · cited 2×
“, 2015 [39] range 0.”
BackgroundInfluentialSkov, M., Pressler, T., Lykkesfeldt, J., Poulsen, H. E., Jensen, P. Ø., Johansen, H. K., Qvist, T., Kræmer, D., Høiby, N., & Ciofu, O. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.09.015 · Cited by 44
Smith, A., Buchinsky, F. J., & Post, J. C. (2011) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599810391620 · Cited by 44 · cited 1×
“Further evidence for the efficacy of NAC in rhinosinusitis comes from the review by Smith and colleagues [64] where TGA was shown to be effective in treating chronic rhinosinusitis and eradicating bacterial biofilms.”
BackgroundBritish Thoracic Society national bronchiectasis audit 2010 and 2011: Figure 1
Hill, A. T., Welham, S. A., Reid, K., Bucknall, C. E., & On behalf of the British Thoracic Society (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201983 · Cited by 42
Priftis, K. Ν., Litt, D. J., Manglani, S., Anthracopoulos, M. Β., Thickett, K. J., Tzanakaki, G., Fenton, P. A., Syrogiannopoulos, G. A., Vogiatzi, A., Douros, K., et al. (2013) · CHEST Journal · doi:10.1378/chest.12-0623 · Cited by 40
Zheng, C. H., Ahmed, K., Rikitomi, N., Martinez, G., & Nagatake, T. (1999) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1999.tb02381.x · Cited by 38 · cited 3×
“M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT [51].”
BackgroundCombined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms
Leite, B., Gomes, F., Teixeira, P., et al. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.11.011 · Cited by 37 · cited 2×
“…have been focused on Aslam et al., 2007 [34] 80 Roveta et al., 2004 [40] 8 Bozzolasco et al., 2002 [41] range 0.007-8 Staphylococcus epidermidis Leite et al., 2013 [42] 4 and 40 Kirmusaoğlu et al., 2012 [43] 0.03, 0.12, 0.5, and 2 Gomes et al., 2012 [44] 4 and 40 Aslam and Darouiche, 2011[33]…”
InfluentialDetection of biofilm in bronchoalveolar lavage from children with non‐cystic fibrosis bronchiectasis
Marsh, R. L., Thornton, R. B., Smith‐Vaughan, H., Richmond, P., Pizzutto, S. J., & Chang, A. B. (2014) · Pediatric Pulmonology · doi:10.1002/ppul.23031 · Cited by 37
N-acetylcysteine Inhibits and Eradicates Candida albicans Biofilms
El-Baky, R. M. A., Ela, D. M. M. A. E., & Gad, G. F. M. (2014) · American journal of infectious diseases and microbiology · doi:10.12691/ajidm-2-5-5 · Cited by 32 · cited 1×
“, 2014 [47]; range 0.”
Chavez‐Dozal, A. A., Lown, L., Jahng, M., Walraven, C. J., & Lee, S. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03137-14 · Cited by 32
Grassi, C., & Benedetto, F. D. (2002) · Journal of Chemotherapy · doi:10.1179/joc.2002.14.3.279 · Cited by 17 · cited 1×
“[58,59] A multicenter double blind study [60] on 180 patients with acute bronchitis, tracheobronchitis, or acute exacerbations of chronic bronchitis compared the effects of thiamphenicol glycinate acetylcysteinate (TGA;n=92) and thiamphenicol glycinate (TG; n=88), both administered by aerosol.”
BackgroundThe effect of N-acetylcysteine on growth and biofilm formation in Staphylococcus epidermidis strains
Kırmusaoğlu, S., Yurdugül, S., & Koçoğlu, E. (2012) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1103-4 · Cited by 7 · cited 1×
“…al., 2007 [34] 80 Roveta et al., 2004 [40] 8 Bozzolasco et al., 2002 [41] range 0.007-8 Staphylococcus epidermidis Leite et al., 2013 [42] 4 and 40 Kirmusaoğlu et al., 2012 [43] 0.03, 0.12, 0.5, and 2 Gomes et al., 2012 [44] 4 and 40 Aslam and Darouiche, 2011[33] 80 El Feki et al., 2009 [30] 2…”
Influential
Cited by
Pedre, B., Barayeu, U., Ezeriņa, D., & Dick, T. P. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107916 · Cited by 470
Raghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
Metadata
- Authors
- Blasi, F., Page, C., Rossolini, G. M., Pallecchi, L., Matera, M. G., Rogliani, P., & Cazzola, M.
- Venue
- Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 117
- Pages
- 190-197
- ISSN
- 0954-6111 (ISSN-L)
- OpenAlex
- W2430858641
- Cited by
- 206
- References
- 53
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.